Buchumschlag

366 | EVOLVING TREATMENT LANDSCAPE AND OUTCOMES IN ELDERLY HODGKIN LYMPHOMA: A 15‐YEAR MULTICENTER RETROSPECTIVE ANALYSIS FROM CHINA HIGHLIGHTING THE IMPACT OF NOVEL THERAPIES

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	P. Zhao, M. Bai, C. Huang, J. Wang, Y. Li, Y. Jiang, G. Wang, F. Zhu, S. Zhao, W. Guo, S. Qiao, H. Geng, J. He, J. Ma, S. Chen, D. Song, J. Xu, O. Bai, H. Zhou, Q. Zhang, L. Su, H. Zhang
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Hematological Oncology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

674 | CLINICOPATHOLOGICAL CHARACTERISTICS, TREATMENT RESPONSE, AND PROGNOSTIC FACTORS OF PATIENTS WITH INTRAVASCULAR LARGE B CELL LYMPHOMA: A MULTICENTER STUDY IN CHINA
von: Y. Guo, et al.
Veröffentlicht: (2025)

745 | CLINICAL OUTCOMES AND PROGNOSTIC FACTORS IN EXTRANODAL NK/T‐CELL LYMPHOMA: A 12‐YEAR RETROSPECTIVE STUDY FROM A SINGLE CENTER
von: H. Huang, et al.
Veröffentlicht: (2025)

638 | IMPACT OF FIRST‐LINE SETTING MAINTENANCE THERAPY ON PROGNOSIS IN DIFFUSE LARGE B‐CELL LYMPHOMA: A MULTICENTER RETROSPECTIVE STUDY
von: L. Lyu, et al.
Veröffentlicht: (2025)

756 | REAL‐WORLD STUDY OF GOLIDOCITINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA: RETROSPECTIVE DATA FROM MEDICAL CENTERS IN CHINA
von: H. Huang, et al.
Veröffentlicht: (2025)

720 | THE TREATMENT EVOLUTION OF CLASSIC HODGKIN LYMPHOMA OVER TWO DECADES IN CHINA: REAL‐WORLD EXPERIENCES OF AN ACADEMIC CENTER
von: Z. He, et al.
Veröffentlicht: (2025)

581 | THE BURDEN OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN ENGLAND: A RETROSPECTIVE ANALYSIS OF REAL‐WORD TREATMENT PATTERNS AND OUTCOMES
von: A. Zaffalon, et al.
Veröffentlicht: (2025)

596 | THE BURDEN OF RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA IN ENGLAND: A RETROSPECTIVE ANALYSIS OF REAL‐WORD TREATMENT PATTERNS AND OUTCOMES
von: A. Zaffalon, et al.
Veröffentlicht: (2025)

589 | THE EFFICACY AND SAFETY OF ORELABRUTINIB‐BASED REGIMENS IN THE TREATMENT OF MARGINAL ZONE LYMPHOMA: A RETROSPECTIVE REAL‐WORLD STUDY
von: H. Li, et al.
Veröffentlicht: (2025)

665 | REAL WORLD OUTCOMES OF DIFFUSE LARGE B CELL LYMPHOMA IN BRAZIL CONFIRM THE PROGNOSTIC IMPACT OF CELL OF ORIGIN: BRA‐DLBCL MULTICENTER RETROSPECTIVE STUDY.
von: G. F. Perini, et al.
Veröffentlicht: (2025)

358 | PD‐1‐BASED SALVAGE THERAPY FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER REAL‐WORLD ANALYSIS
von: H. Tharmaseelan, et al.
Veröffentlicht: (2025)

764 | REAL‐WORLD OUTCOMES OF MITOXANTRONE HYDROCHLORIDE LIPOSOME REGIMEN FOR PERIPHERAL T‐CELL LYMPHOMA: THE EFFICACY AND SAFETY ANALYSIS OF TREATMENT‐NAÏVE POPULATION
von: D. Zhao, et al.
Veröffentlicht: (2025)

613 | LIMITED‐STAGE MANTLE CELL LYMPHOMA: CLINICAL FEATURES, MANAGEMENT, AND OUTCOMES IN A MULTICENTER RETROSPECTIVE STUDY FROM SPAIN
von: S. D. R. V. Cozzarelli, et al.
Veröffentlicht: (2025)

594 | MULTICENTER RETROSPECTIVE COHORT STUDY OF 805 PATIENTS WITH OCULAR ADNEXAL MARGINAL ZONE B‐CELL LYMPHOMA ON BEHALF OF THE CHINESE OCULAR LYMPHOMA COLLABORATIVE GROUP
von: X. Li, et al.
Veröffentlicht: (2025)

634 | OPTIMAL TREATMENT FOR DOUBLE‐EXPRESSOR LYMPHOMA IN THE ERA OF NOVEL AGENTS: A SYSTEMATIC REVIEW AND META‐ANALYSIS
von: M. Zhang, et al.
Veröffentlicht: (2025)

881 | EPIDEMIOLOGY, TREATMENT PATTERN AND SURVIVAL OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION‐ASSOCIATED LYMPHOMA IN CHINA
von: C. Wang, et al.
Veröffentlicht: (2025)

735 | OUTCOMES IN DOUBLE‐EXPOSED CLASSICAL HODGKIN LYMPHOMA: IMPACT OF TREATMENT SEQUENCE AND SALVAGE STRATEGIES AFTER BRENTUXIMAB VEDOTIN AND CHECKPOINT INHIBITOR FAILURE
von: M. Marinoni, et al.
Veröffentlicht: (2025)

641 | OUTCOMES OF DOSE ADJUSTED R‐EPOCH IN ELDERLY PATIENTS: A RETROSPECTIVE STUDY
von: G. Kaleka, et al.
Veröffentlicht: (2025)

630 | POLATUZUMAB VEDOTIN‐BASED COMBINATION THERAPY DEMONSTRATES EFFICACY AND SAFETY IN ELDERLY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS
von: W. Guo, et al.
Veröffentlicht: (2025)

759 | UPDATED OUTCOMES OF P‐GEMD IN TREATMENT‐NAÏVE EARLY‐STAGE NON‐UPPER AERO‐DIGESTIVE TRACT OR ADVANCED‐STAGE EXTRANODAL NK/T CELL LYMPHOMA
von: J. Liang, et al.
Veröffentlicht: (2025)

645 | REAL‐WORLD TREATMENT PATTERNS AND SURVIVAL OUTCOMES OF DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS FROM A COMPREHENSIVE PORTUGUESE CANCER CENTER
von: I. O. Ramos, et al.
Veröffentlicht: (2025)

863 | RADIOTHERAPY IN PREGNANT PATIENTS WITH HODGKIN’S LYMPHOMA: CLINICAL OUTCOMES AND DOSIMETRIC ASSESSMENT
von: E. Wojciechowska‐Lampka, et al.
Veröffentlicht: (2025)

586 | OBINUTUZUMAB COMBINED WITH BENDAMUSTINE IN THE TREATMENT OF MATURE B‐CELL LYMPHOMA: AN OPEN‐LABEL, MULTICENTER STUDY
von: Y. Yan, et al.
Veröffentlicht: (2025)

513 | PROGNOSTIC PREDICTIVE VALUE OF BASELINE 18F‐FDG PET/CT METABOLIC PARAMETERS IN HODGKIN’S LYMPHOMA
von: H. Zhang, et al.
Veröffentlicht: (2025)

362 | BRENTUXIMAB VEDOTIN‐ICE AS SALVAGE TREATMENT PRIOR TO STEM CELL TRANSPLANT IN REFRACTORY AND RELAPSED HODGKIN LYMPHOMA PATIENTS. A MULTICENTER REAL‐WORLD EXPERIENCE
von: P. Dutari, et al.
Veröffentlicht: (2025)

635 | SYMPTOM BURDEN AND HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH AGGRESSIVE NON‐HODGKIN LYMPHOMA IN CHINA: A CROSS‐SECTIONAL STUDY
von: J. Jin, et al.
Veröffentlicht: (2025)

650 | EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL: A RETROSPECTIVE ANALYSIS OF REAL‐WORLD DATA
von: S. Yang, et al.
Veröffentlicht: (2025)

129 | PEMBROLIZUMAB AND RADIATION THERAPY ALONE AS AN ALTERNATIVE TO TRANSPLANT FOR LOCALIZED FAILURE AFTER CHEMOTHERAPY IN HODGKIN LYMPHOMA: A MULTICENTER PHASE II STUDY
von: A. D. Dreyfuss, et al.
Veröffentlicht: (2025)

684 | MECAPEGFILGRASTIM FOR PROPHYLAXIS OF CHEMOTHERAPY‐INDUCED NEUTROPENIA IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A MULTICENTER PILOT TRIAL
von: J. Wang, et al.
Veröffentlicht: (2025)

744 | IMPACT OF RELATIVE DOSE INTENSITY OF CHEMOTHERAPY IN ELDERLY PATIENTS WITH EXTRANODAL NK/T‐CELL LYMPHOMA
von: W. Zhao, et al.
Veröffentlicht: (2025)

743 | ROLE OF CONSOLIDATION AFTER BRENTUXIMAB VEDOTIN TREATMENT IN RELAPSED/REFRACTORY MYCOSIS FUNGOIDES: POLISH LYMPHOMA RESEARCH GROUP RETROSPECTIVE MULTICENTER STUDY
von: E. Chmielowska, et al.
Veröffentlicht: (2025)

721 | TISLELIZUMAB COMBINED WITH CPEL (CHIDAMIDE, PREDNISONE, ETOPOSIDE, LENALIDOMIDE) FOLLOWED AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA
von: Y. Wang, et al.
Veröffentlicht: (2025)

748 | EFFECTIVENESS AND SAFETY OF LINPERLISIB IN PATIENTS WITH MATURE T/NK‐CELL LYMPHOMA: A REAL‐WORLD RETROSPECTIVE STUDY
von: Z. Li, et al.
Veröffentlicht: (2025)

284 | NOVEL ZCR (ZANUBRUTINIB, CHIDAMIDE, RITUXIMAB) ± CHOP REGIMEN DEMONSTRATES PROMISING EFFICACY IN FRONTLINE TREATMENT OF DOUBLE‐EXPRESSOR DIFFUSE LARGE B‐CELL LYMPHOMA
von: Z. Li, et al.
Veröffentlicht: (2025)

294 | CLINICAL PRACTICE PATTERN AND OUTCOMES IN DLBCL WITH DISTINCT GENETIC SUBTYPES: A LARGE‐SCALE REAL‐WORLD STUDY FROM CHINA
von: P. Xu, et al.
Veröffentlicht: (2025)

824 | R‐CHOP WITH SINTILIZUMAB IN FIRST‐LINE TREATMENT OF LARGE B‐CELL LYMPHOMA PATIENTS WITH TP53 MUTATIONS AND PD‐L1 EXPRESSION: A RANDOMIZED, MULTICENTER CLINICAL STUDY
von: Y. Che, et al.
Veröffentlicht: (2025)

666 | OUTCOMES OF RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN AN ASIAN MULTIETHNIC COHORT
von: N. Lim, et al.
Veröffentlicht: (2025)

644 | EFFICACY OF ZANUBRUTINIB IN NEWLY DIAGNOSED MYD88‐MUTATED DIFFUSE LARGE B‐CELL LYMPHOMA: A RETROSPECTIVE SINGLE‐CENTER REAL‐WORLD STUDY
von: W. Huang, et al.
Veröffentlicht: (2025)

785 | HEMATOLOGIC TOXICITY ANALYSIS OF CAR‐T CELL THERAPY: A RETROSPECTIVE REAL‐WORLD STUDY
von: H. Wang, et al.
Veröffentlicht: (2025)

231 | IMPACT OF RITUXIMAB EARLY ADMINISTRATION ON OUTCOMES IN ADVANCED STAGE LOW TUMOR BURDEN FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF PHASE III JCOG1411/FLORA STUDY
von: D. Maruyama, et al.
Veröffentlicht: (2025)

696 | OUTCOME DISPARITIES IN PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS AT AN ACADEMIC CENTER WITH A PREDOMINANTLY HISPANIC PATIENT POPULATION
von: Y. Teklie, et al.
Veröffentlicht: (2025)